In the comment section of a recent article of mine, a reader suggested that I, or really anyone who isn’t a medical professional or operating in the pharmaceutical sales industry, for that matter, shouldn’t be investing in biotech stocks. Their point, and I’m trying to simplify this as much as possible for the sake of expediency, was that there is simply too much potential risk associated with the rather speculative science that these companies are making. We all know how volatile the biotech space can be.
